FDA yesterday approved the respiratory syncytial virus vaccine, adjuvanted (Arexvy, GlaxoSmithKline Biologicals) for the prevention of lower respiratory tract disease (LRTD) caused by RSV in
Two approaches for using observational data to emulate clinical trials are presented in a Research and Reporting Methods article. “Addressing the issues discussed in this
The immunomodulatory “off-target” effects of bacille Calmette–Guérin Denmark (BCG-Denmark) vaccine did not lower the risk of COVID-19 in health care workers in a placebo-controlled, international, double-blind
Following FDA regulatory action (see Wednesday’s PNN), CDC has taken steps to simplify COVID-19 vaccine recommendations and allow more flexibility for people at higher risk
FDA yesterday took a number of important steps to simplify the use of the bivalent mRNA COVID-19 vaccines. The Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA
In the 9 influenza seasons after the 2009 A(H1N1) pandemic, vaccinations provided “substantial benefit against outpatient illness,” according to a CDC study, with vaccine effectiveness
Administered during the last trimester of pregnancy, a bivalent respiratory syncytial virus (RSV) prefusion F protein–based (RSVpreF) vaccine reduced medically attended severe RSV-associated lower respiratory
In the RENOIR trial, an investigational bivalent respiratory syncytial virus (RSV) prefusion F protein–based (RSVpreF) vaccine “prevented RSV-associated lower respiratory tract illness and RSV-associated acute
Even if vaccinated, individuals with common comorbidities must remain vigilant against SARS-CoV-2 infection, investigators conclude based on analysis of data in the Truveta patient population.
Policymakers and public health officials can learn much from the COVID-19 pandemic, including how COVID-19 pandemic policies and behaviors affected economic and educational outcomes, as